Cytosorbents (CTSO) Net Cash Flow Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.71 Bn | 99.49 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.50 Bn | 67.05 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.59 Bn | 44.92 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.40 Bn | 27.29 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.50 Bn | 22.37 Bn | 2.07 Bn | -48.90% |
| 10 | Cytosorbents | 22.59 Mn | 17.79 Mn | 6.13 Mn | 27.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.01% |
| Dec 31, 2025 | -69.01% |
| Sep 30, 2025 | 30.31% |
| Jun 30, 2025 | 49.48% |
| Mar 31, 2025 | 33.30% |
| Dec 31, 2024 | 31.80% |
| Sep 30, 2024 | 14.40% |
| Jun 30, 2024 | 54.70% |
| Mar 31, 2024 | -24.37% |
| Dec 31, 2023 | 32.84% |
| Sep 30, 2023 | -27.88% |
| Jun 30, 2023 | -38.83% |
| Mar 31, 2023 | -30.44% |
| Dec 31, 2022 | 47.40% |
| Sep 30, 2022 | -190.68% |
| Jun 30, 2022 | -56.25% |
| Mar 31, 2022 | -49.29% |
| Dec 31, 2021 | -41.54% |
| Sep 30, 2021 | -136.73% |
| Jun 30, 2021 | -38.94% |